HRP20210668T1 - Orodisperzibilna tableta koja sadrži estetrol - Google Patents
Orodisperzibilna tableta koja sadrži estetrol Download PDFInfo
- Publication number
- HRP20210668T1 HRP20210668T1 HRP20210668TT HRP20210668T HRP20210668T1 HR P20210668 T1 HRP20210668 T1 HR P20210668T1 HR P20210668T T HRP20210668T T HR P20210668TT HR P20210668 T HRP20210668 T HR P20210668T HR P20210668 T1 HRP20210668 T1 HR P20210668T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage unit
- weight
- particles
- cellulose
- combinations
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title claims 11
- 229950009589 estetrol Drugs 0.000 title claims 10
- 239000002245 particle Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 23
- 239000007788 liquid Substances 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- 239000007787 solid Substances 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 5
- 235000010980 cellulose Nutrition 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 235000014633 carbohydrates Nutrition 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000000811 xylitol Substances 0.000 claims 3
- 235000010447 xylitol Nutrition 0.000 claims 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 3
- 229960002675 xylitol Drugs 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 239000004386 Erythritol Substances 0.000 claims 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229950008138 carmellose Drugs 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 235000019414 erythritol Nutrition 0.000 claims 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 2
- 229940009714 erythritol Drugs 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000000845 maltitol Substances 0.000 claims 2
- 235000010449 maltitol Nutrition 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 229940035436 maltitol Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000019426 modified starch Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000000748 compression moulding Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Claims (34)
1. Čvrsta farmaceuatska orodisperzibilna jedinica za doziranje koja ima masu između 30 i 1000 mg, navedena jedinica za doziranje sadrži najmanje 100 μg estetrolske komponente odabrane između estetrola, estera estetrola i njihovih kombinacija;
pri čemu se čvrsta jedinica za doziranje može dobiti postupkom koji obuhvaća:
• pribavljanje čestica nosača koje imaju prosječno ponderiranu veličinu čestice od 10 μm do 400 μm;
• pribavljanje tekućine za punjenje koja sadrži najmanje 50 % masenog udjela organskog otapala odabranog između metanola, etanola, izopropanola, acetona te njihovih kombinacija; 1-50 % masenog udjela estetrolske komponente, te opcionalno 0-49 % masenog udijela jednog ili više ostalih farmaceutski prihvatljivih sastojaka;
• miješanje 1 masenog dijela tekućine za punjenje sa 0.5-20 masenih dijelova čestica nosača kako bi se proizvele mokre čestice;
• uklanjanje organskog otapala iz mokrih čestica kako bi se proizvele napunjene čestice;
• opcionalno miješanje napunjenih čestica s jednim ili više ekscipijensa za tabletiranje; te
• formiranje napunjenih čestica ili smjese napunjenih čestica i jednog ili više ekscipijenasa za tabletiranje u čvrstu jedinicu za doziranje.
2. Jedinica za doziranje prema zahtjevu 1, pri čemu jedinica za doziranje ima masu između 40 i 500 mg.
3. Jedinica za doziranje prema zahtjevu 1 ili 2, pri čemu jedinica za doziranje sadrži 0.3-100 mg estetrolske komponente.
4. Jedinica za doziranje prema bilo kojem od prethodnih zahtjeva, pri čemu je estetrolska komponenta estetrol.
5. Jedinica za doziranje prema bilo kojem od prethodnih zahtjeva, pri čemu jedinica za doziranje sadrži 30-99.9 % vodotopljivih ugljikohidrata odabranih između maltoze, fruktoze, saharoze, laktoze, glukoze, galaktoze, trehaloze, ksilitola, sorbitola, eritritola, maltitola, manitola, izomalta te njihovih kombinacija.
6. Jedinica za doziranje prema zahtjevu 5, pri čemu jedinica za doziranje sadrži najmanje 20 % masenog udjela manitola.
7. Jedinica za doziranje prema bilo kojem od prethodnih zahtjeva, pri čemu jedinica za doziranje sadrži 0.1-20 % masenog udjela veziva odabranog između derivata celuloze, polietilen glikola te njihovih kombinacija.
8. Jedinica za doziranje prema zahtjevu 7, pri čemu je vezivo derivat celuloze.
9. Jedinica za doziranje prema zahtjevu 7 ili 8, pri čemu su derivati celuloze odabrani između hidroksipropil celuloze, hidroksietil celuloze, hidroksimetil celuloze, hidroksipropilmetil celuloze, metil celuloze, etil celuloze, karboksimetil celuloze te njihovih kombinacija.
10. Jedinica za doziranje prema zahtjevu 9, pri čemu je derivat celuloze etilceluloza.
11. Jedinica za doziranje prema bilo kojem od prethodnih zahtjeva, pri čemu jedinica za doziranje sadrži 0.1-20 % masenog udjela sredstva za raspadanje odabranog između modificiranih škrobova, umreženog polivinilpirolidona, umrežene karmeloze te njihovih kombinacija.
12. Čvrsta jedinica za doziranje prema bilo kojem od prethodnih zahtjeva za upotrebu u medicinskom liječenju, navedena upotreba uključuje sublingvalnu, bukalnu ili sublabijalnu primjenu jedinice za doziranje.
13. Čvrsta jedinica za doziranje prema bilo kojem od zahtjeva 1-11 za upotrebu u zamjenskoj hormonskoj terapiji žena, navedena upotreba obuhvaća sublingvalnu, bukalnu ili sublabijalnu primjenu jedinice za doziranje.
14. Čvrsta jedinica za doziranje za upotrebu prema zahtjevu 12 ili 13, pri čemu navedena upotreba obuhvaća primjenu jednom dnevno tijekom razdoblja od najmanje 1 tjedan.
15. Postupak za žensku kontracepciju, navedeni postupak uključuje sublingvalnu, bukalnu ili sublabijalnu primjenu jedinice za doziranje prema bilo kojem od zahtjeva 1-11.
16. Postupak prema zahtjevu 15, navedeni postupak obuhvaća primjenu jednom dnevno tijekom razdoblja od najmanje 1 tjedan.
17. Postupak za pripremu čvrste jedinice za doziranje prema bilo kojem od prethodnih zahtjeva, pri čemu navedeni postupak obuhvaća korake:
• pribavljanje čestica nosača koje imaju prosječno ponderiranu veličinu čestice od 10 μm do 400 μm;
• pribavljanje tekućine za punjenje koja sadrži najmanje 50 % masenog udjela organskog otapala odabranog između metanola, etanola, izopropanola, acetona te njihovih kombinacija; 1-50 % masenog udjela estetrolske komponente, te 0-49 % masenog udijela jednog ili više ostalih farmaceutski prihvatljivih sastojaka;
• miješanje 1 masenog dijela tekućine za punjenje sa 0.5-20 masenih dijelova čestica nosača kako bi se proizvele mokre čestice;
• uklanjanje organskog otapala iz mokrih čestica kako bi se proizvele napunjene čestice;
• opcionalno miješanje napunjenih čestica s jednim ili više ekscipijensa za tabletiranje; te
• formiranje napunjenih čestica ili smjese napunjenih čestica i jednog ili više ekscipijenasa za tabletiranje u čvrstu jedinicu za doziranje.
18. Postupak prema zahtjevu 17, u kojem čestice nosača sadrže najmanje 30 % masenog udjela vodotopljivih ugljikohidrata odabranih između monosaharida, disaharida, trisaharida, C4-C12 šećernog alkohola te njihovih kombinacija.
19. Postupak prema zahtjevu 18, u kojem čestice nosača sadrže najmanje 50 % masenog udjela vodotopljivih ugljikohidrata.
20. Postupak prema zahtjevu 18 ili 19, u kojem su vodotopljivi ugljikohidrati odabrani između maltoze, fruktoze, saharoze, laktoze, glukoze, galaktoze, trehaloze, ksilitola, sorbitola, eritritola, maltitola, manitola te njihovih kombinacija.
21. Postupak prema bilo kojem od zahtjeva 17-20, u kojem čestice nosača sadrže najmanje 20 % masenog udjela manitola.
22. Postupak prema bilo kojem od zahtjeva 17-21, u kojem čestice nosača sadrže najmanje 10 % masenog udjela laktoze.
23. Postupak prema bilo kojem od zahtjeva 17-22, u kojem se više od 90 % masenog udjela estetrolske komponente u tekućini za punjenje otopi kada se tekućina za punjenje pomiješa sa česticama nosača.
24. Postupak prema bilo kojem od zahtjeva 17-23, u kojem tekućina za punjenje sadrži 2-40 % masenog udjela estetrolske komponente.
25. Postupak prema bilo kojem od zahtjeva 17-24, u kojem tekućina za punjenje sadrži 0.5-40 % masenog udjela veziva odabranog između derivata celuloze, polietilen glikola te njihovih kombinacija.
26. Postupak prema zahtjevu 25, u kojem je vezivo etil celuloza.
27. Postupak prema bilo kojem od zahtjeva 17-26, u kojem se mokre čestice proizvode kombiniranjem tekućine za punjenje i čestica nosača u granulatoru s visokim smicanjem, granulatoru s niskim smicanjem ili u granulatoru s fluidnim ležajem.
28. Postupak prema bilo kojem od zahtjeva 17-27, u kojem se organsko otapalo uklanja iz mokrih čestica u granulatoru s fluidnim ležajem.
29. Postupak prema bilo kojem od zahtjeva 17-28, u kojem tekućina za punjenje sadrži najmanje 60 % masenog udjela etanola.
30. Postupak prema bilo kojem od zahtjeva 17-29, u kojem se mokre čestice pripremaju miješanjem tekućine za punjenje sa česticama nosača u masenom omjeru koji je u rasponu od 1:0.8 do 1:12.
31. Postupak prema bilo kojem od zahtjeva 17-30, u kojem napunjene čestice imaju medijalni volumni promjer u rasponu od 100-4000 μm.
32. Postupak prema bilo kojem od zahtjeva 17-31, u kojem ekscipijensi za tabletiranje sadrže 0-15 % masenog udjela jedinice za doziranje sredstva za raspadanje odabranog između modificiranih škrobova, umreženog polivinil pirolidona, umrežene karmeloze te njihovih kombinacija.
33. Postupak prema bilo kojem od zahtjeva 17-32, u kojem jedan ili više ekscipijenasa za tabletiranje sadrže najmanje 30% masenog udjela jedinice za doziranje eksipijensa odabranog između laktoze, manitola, ksilitola, mikrokristalne celuloze, škroba, kroskarmeloze natrija, polivinil pirolidona te njihovih kombinacija.
34. Postupak prema bilo kojem od zahtjeva 17-33, u kojem je čvrsta jedinica za doziranje formirana izravnim komprimiranjem ili kompresijskim prešanjem.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172751 | 2015-06-18 | ||
PCT/EP2016/064071 WO2016203009A1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible tablet containing estetrol |
EP16729601.1A EP3310345B1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible tablet containing estetrol |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210668T1 true HRP20210668T1 (hr) | 2021-05-28 |
Family
ID=53476700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210668TT HRP20210668T1 (hr) | 2015-06-18 | 2021-04-26 | Orodisperzibilna tableta koja sadrži estetrol |
Country Status (18)
Country | Link |
---|---|
US (1) | US10894014B2 (hr) |
EP (1) | EP3310345B1 (hr) |
JP (1) | JP6866561B2 (hr) |
CN (1) | CN107810001A (hr) |
CA (1) | CA2988485A1 (hr) |
CY (1) | CY1124104T1 (hr) |
DK (1) | DK3310345T3 (hr) |
ES (1) | ES2877186T3 (hr) |
HR (1) | HRP20210668T1 (hr) |
HU (1) | HUE054589T2 (hr) |
LT (1) | LT3310345T (hr) |
MA (1) | MA44205B1 (hr) |
MD (1) | MD3310345T2 (hr) |
PL (1) | PL3310345T3 (hr) |
PT (1) | PT3310345T (hr) |
RS (1) | RS61812B1 (hr) |
SI (1) | SI3310345T1 (hr) |
WO (1) | WO2016203009A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013030830B1 (pt) | 2011-06-01 | 2019-12-03 | Estetra S A | processo para a preparação de um composto de fórmula (i) e processo de preparação de estetrol |
KR101957937B1 (ko) | 2011-06-01 | 2019-03-14 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
PL3310333T3 (pl) | 2015-06-18 | 2020-07-13 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
ES2877186T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
ES2877476T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
EP4056638A4 (en) * | 2019-11-07 | 2022-11-30 | Asahi Kasei Kabushiki Kaisha | CELLULOSIC COMPOSITION, TABLET AND DISCOMPOSING TABLET IN THE MOUTH |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
ES2258037T3 (es) | 1999-12-02 | 2006-08-16 | Akzo Nobel N.V. | Androgenos sustituidos con 14,15-beta-metilen. |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
DE10044241A1 (de) * | 2000-09-07 | 2002-03-21 | Mahle Gmbh | Kolbenring für Kolben-Maschine |
EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
ATE350041T1 (de) | 2001-05-18 | 2007-01-15 | Pantarhei Bioscience Bv | Pharmaceutishe zusammensetzung für die hormonersatztherapie |
DE60223795T2 (de) | 2001-05-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption |
EP1390041B1 (en) | 2001-05-23 | 2009-11-25 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
DE60216630T2 (de) | 2001-11-15 | 2007-09-20 | Pantarhei Bioscience B.V. | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
EA007599B1 (ru) | 2002-02-21 | 2006-12-29 | Шеринг Акциенгезельшафт | Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
AU2003274941A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
SI1511496T1 (sl) | 2002-06-11 | 2007-04-30 | Pantarhei Bioscience Bv | Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo |
CA2492287C (en) | 2002-07-12 | 2011-12-13 | Pantarhei Bioscience B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
UA82851C2 (en) | 2002-08-28 | 2008-05-26 | Estrogen replacement regimen in menopausal women | |
AU2003274823A1 (en) | 2002-10-23 | 2004-05-13 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
EP1558265B1 (en) | 2002-11-05 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Use of drospirenone for the treatment of hypertension |
CA2505190C (en) | 2002-11-08 | 2012-07-10 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
EP1624878B1 (en) | 2003-05-22 | 2006-09-27 | Pantarhei Bioscience B.V. | Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
DK1670440T3 (da) | 2003-09-29 | 2014-07-07 | Novo Nordisk As | HRT formuleringer |
ES2933479T3 (es) | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
EP1755562B1 (de) | 2004-05-28 | 2013-10-09 | Richter Gedeon Nyrt. | Folsäurehaltiges kontrazeptivum |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
ES2558030T3 (es) | 2006-03-02 | 2016-02-01 | Warner Chilcott Company, Llc | Método anticonceptivo oral multifásico de ciclo prolongado |
ES2659316T3 (es) | 2006-06-08 | 2018-03-14 | Allergan Pharmaceuticals International Limited | Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
KR20090029824A (ko) | 2006-07-06 | 2009-03-23 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임용 및 선천성 기형 위험 예방용 제약 제제 |
CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
CL2007003429A1 (es) | 2006-11-29 | 2008-04-11 | Wyeth Corp | Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti |
EP2124900B1 (en) | 2006-12-20 | 2014-12-03 | Teva Women's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
CA2674325A1 (en) | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
MX2009007254A (es) | 2007-01-12 | 2009-08-12 | Wyeth Corp | Composiciones de tableta en tableta. |
US8367647B2 (en) | 2007-06-21 | 2013-02-05 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
PL2170346T3 (pl) | 2007-07-19 | 2012-03-30 | Pantarhei Bioscience Bv | Leczenie lub profilaktyka zaburzeń związanych z nadciśnieniem w okresie ciąży lub opóźnienie wzrostu płodu |
US20110250274A1 (en) * | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
CN101780073B (zh) * | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | 非布司他分散片药物及其制备方法 |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
JP5801801B2 (ja) | 2009-06-23 | 2015-10-28 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 緊急避妊のための医薬組成物及び処置方法 |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
CN102985070A (zh) | 2010-04-15 | 2013-03-20 | 拜耳知识产权有限责任公司 | 用于hrt的极低剂量的固体口服剂型 |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
KR101957937B1 (ko) | 2011-06-01 | 2019-03-14 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
BR112013030830B1 (pt) | 2011-06-01 | 2019-12-03 | Estetra S A | processo para a preparação de um composto de fórmula (i) e processo de preparação de estetrol |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
HUE025350T2 (en) | 2011-07-19 | 2016-02-29 | Pantarhei Bioscience Bv | Tablets containing dehydroepiandrosterone (DHEA) |
ME02723B (me) | 2011-08-11 | 2017-10-20 | Estetra Sprl | Upotreba estetrola kao kontraceptivnog sredstva u hitnim slučajevima |
CA2848785A1 (en) | 2011-09-16 | 2013-03-21 | Ferring B.V. | A fast dissolving pharmaceutical composition |
JP6196625B2 (ja) | 2011-10-07 | 2017-09-13 | エステトラ エス.ペ.エール.エル. | エステトロールを製造するための方法 |
EP2790688B1 (en) | 2011-12-13 | 2019-11-20 | Arstat, Inc. | A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen |
EP2653163A1 (en) * | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
US9238265B2 (en) * | 2012-09-27 | 2016-01-19 | General Electric Company | Backstrike protection during machining of cooling features |
WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
WO2014189836A1 (en) | 2013-05-21 | 2014-11-27 | Bradley Robinson | Therapeutic and method of use |
US9988417B2 (en) | 2013-09-18 | 2018-06-05 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
US10857080B2 (en) * | 2013-12-04 | 2020-12-08 | Galderma Research & Development | Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics |
ES2655076T3 (es) | 2013-12-12 | 2018-02-16 | Donesta Bioscience B.V. | Unidad de dosificación sólida de desintegración oral con un componente de estetrol |
CA2962921A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions and methods for maintaining cognitive function |
US20180125860A1 (en) | 2015-05-18 | 2018-05-10 | Agile Therapeutics, Inc. | Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects |
ES2877186T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
PL3310333T3 (pl) | 2015-06-18 | 2020-07-13 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
ES2877476T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
HRP20240121T8 (hr) | 2015-06-23 | 2024-05-10 | Laboratorios Leon Farma Sa | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine |
CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
UA126746C2 (uk) | 2018-02-07 | 2023-01-18 | Естетра Спрл | Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи |
-
2016
- 2016-06-17 ES ES16729601T patent/ES2877186T3/es active Active
- 2016-06-17 LT LTEP16729601.1T patent/LT3310345T/lt unknown
- 2016-06-17 SI SI201631167T patent/SI3310345T1/sl unknown
- 2016-06-17 JP JP2017564396A patent/JP6866561B2/ja active Active
- 2016-06-17 MA MA44205A patent/MA44205B1/fr unknown
- 2016-06-17 CA CA2988485A patent/CA2988485A1/en not_active Abandoned
- 2016-06-17 MD MDE20180402T patent/MD3310345T2/ro unknown
- 2016-06-17 PL PL16729601T patent/PL3310345T3/pl unknown
- 2016-06-17 EP EP16729601.1A patent/EP3310345B1/en active Active
- 2016-06-17 RS RS20210512A patent/RS61812B1/sr unknown
- 2016-06-17 HU HUE16729601A patent/HUE054589T2/hu unknown
- 2016-06-17 CN CN201680035673.8A patent/CN107810001A/zh active Pending
- 2016-06-17 PT PT167296011T patent/PT3310345T/pt unknown
- 2016-06-17 DK DK16729601.1T patent/DK3310345T3/da active
- 2016-06-17 WO PCT/EP2016/064071 patent/WO2016203009A1/en active Application Filing
- 2016-06-17 US US15/737,233 patent/US10894014B2/en active Active
-
2021
- 2021-04-26 HR HRP20210668TT patent/HRP20210668T1/hr unknown
- 2021-05-05 CY CY20211100379T patent/CY1124104T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT3310345T (pt) | 2021-05-28 |
PL3310345T3 (pl) | 2021-10-18 |
LT3310345T (lt) | 2021-06-25 |
CY1124104T1 (el) | 2022-05-27 |
RS61812B1 (sr) | 2021-06-30 |
EP3310345A1 (en) | 2018-04-25 |
SI3310345T1 (sl) | 2021-05-31 |
ES2877186T3 (es) | 2021-11-16 |
CA2988485A1 (en) | 2016-12-22 |
US10894014B2 (en) | 2021-01-19 |
EP3310345B1 (en) | 2021-03-31 |
MA44205A (fr) | 2018-04-25 |
CN107810001A (zh) | 2018-03-16 |
JP2018517718A (ja) | 2018-07-05 |
WO2016203009A1 (en) | 2016-12-22 |
HUE054589T2 (hu) | 2021-09-28 |
DK3310345T3 (da) | 2021-05-25 |
MA44205B1 (fr) | 2021-04-30 |
MD3310345T2 (ro) | 2021-07-31 |
JP6866561B2 (ja) | 2021-04-28 |
US20180185271A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210668T1 (hr) | Orodisperzibilna tableta koja sadrži estetrol | |
HRP20200850T1 (hr) | Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola | |
HRP20210555T1 (hr) | Orodisperzibilna tableta koja sadrži estetrol | |
FI2346495T4 (fi) | Farmaseuttinen formulaatio 514 | |
HRP20180129T1 (hr) | Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu | |
US10632074B2 (en) | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product | |
AU2007276874B2 (en) | Granular pharmaceutical compositions | |
ES2607814T3 (es) | Preparación de tabletas | |
AU2011273519B2 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate | |
TW201904565A (zh) | 控釋藥物組合物及其製備方法 | |
HRP20180889T1 (hr) | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu | |
CN102325526A (zh) | 延长释放的药物制剂 | |
JP2018521985A5 (hr) | ||
JP2018517718A5 (hr) | ||
RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
WO2015071432A1 (en) | Pharmaceutical compositions of ibrutinib | |
US20170258749A1 (en) | Oseltamivir Compositions | |
HRP20131088T1 (hr) | Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena | |
RU2015132902A (ru) | Новый быстрорастворимый состав гранул с улучшенной растворимостью | |
KR101923403B1 (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
ES2663357T3 (es) | Formulaciones de mazindol | |
WO2007086079B1 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
WO2012020301A2 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
JP2015120758A5 (hr) |